Back to search

University of Southampton

Maternal metformin treatment in obese pregnancy alters priming of offspring metabolic dysfunction and non-alcoholic fatty liver disease in mice

Abstract

dc:description.abstract

Background: Interventions to protect offspring from the deleterious long-term effects of maternal obesity during pregnancy have been sought but have proven largely ineffective in humans. Metformin, an antidiabetic drug used to control gestational diabetes, failed to reduce obesity-associated fetal overgrowth in two human trials, yet long-term follow-up of these children will take many years. Thus, this thesis aims to characterize the effect of metformin on offspring in a mouse model of maternal obesity.<br/><br/>Methods: Female mice were fed normal chow (C; 7% kcal fat) or obesogenic high-fat diet (HF; 45% kcal fat) for 6 weeks prior to mating. Metformin (m) was given in drinking water (250mg/kg) to half of dams during pregnancy and lactation. Dam and fetal parameters were assessed in a subgroup at gestation day 16.5. At weaning, offspring received C or HF diet. Offspring metabolic parameters were assessed at 28 weeks, and offspring were killed and tissue collected at 30 weeks. Plasma metabolic and inflammatory markers and hepatic gene expression, lipid levels and pathology were evaluated.<br/><br/>Results: In fetuses, metformin treatment altered fetal hepatic gene expression and reduced fetal weight. Metformin had no effect on obese dam glucose homeostasis. In adult female offspring of obese dams, maternal metformin reduced adiposity, improved glucose homeostasis and reduced nonalcoholic fatty liver disease (NAFLD) severity. In adult male offspring of obese dams, metformin had no beneficial effects. In adult offspring of either sex born to lean dams, maternal metformin increased offspring adiposity, impaired glucose homeostasis and worsened NAFLD severity.<br/><br/>Conclusions: Metformin treatment in obese dams partially protects female offspring from the effects of maternal obesity, yet male offspring do not benefit. Offspring of metformin-treated lean dams, of either sex, have more severe metabolic disease. These data urge investigation of mechanisms priming adverse offspring responses to maternal metformin.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2017

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Thomas, Hugh
Advisors dc:contributor.advisor
  • Byrne, Christopher
  • Cagampang, Felino
ORCID person:identifier.orcid

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Thomas, Hugh. Maternal metformin treatment in obese pregnancy alters priming of offspring metabolic dysfunction and non-alcoholic fatty liver disease in mice. doctoral thesis, University of Southampton, 2017.